SCHEMBL9901510

SCHEMBL9901510

Cc1ccc(Cl)c(C(=O)CBr)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.50
LMNA P02545 4/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
GSK3B P49841 2/20 0.50
KDM4E B2RXH2 1/20 0.50
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
POLB P06746 1/20 0.43
ERCC5 P28715 1/20 0.41
FEN1 P39748 1/20 0.41
CSNK2A1 P68400 1/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
MITF O75030 1/20 0.40
S1PR4 O95977 1/20 0.40
S1PR1 P21453 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL846655 0.85 HPGD (0.50) RAB9ALMNAMEN1KMT2AGSK3B
SCHEMBL1024045 0.83 RAB9A (0.51) RAB9ALMNAMEN1KMT2AKDM4E
SCHEMBL404490 0.81 ERCC5 (0.61) RAB9ALMNAMEN1KMT2AGSK3B
SCHEMBL29391618 0.81 ERCC5 (0.61) RAB9ALMNAMEN1KMT2AGSK3B
SCHEMBL405443 0.81 MEN1 (0.62) RAB9ALMNAMEN1KMT2AGSK3B
SCHEMBL29670000 0.81 MEN1 (0.62) RAB9ALMNAMEN1KMT2AGSK3B
SCHEMBL1024674 0.80 RAB9A (0.49) RAB9ALMNAMEN1KMT2AKDM4E
SCHEMBL3233653 0.79 CSNK2A1 (0.60) RAB9ALMNAMEN1KMT2AGSK3B
SCHEMBL31602938 0.79 CSNK2A1 (0.60) RAB9ALMNAMEN1KMT2AGSK3B
SCHEMBL9926134 0.79 ALDH1A1 (0.56) KMT2AGSK3BPOLBERCC5FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10023567-B2 Imidazole and thiazole compositions for modifying biological signaling OHIO UNIVERSITY (US) 2018-07-17 US disclosed
US-20170210737-A1 IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING OHIO UNIVERSITY (US) 2017-07-27 US disclosed
US-20170196845-A1 PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE OHIO UNIVERSITY (US) 2017-07-13 US disclosed
US-20150210669-A1 COMPOUND FOR THE TREATMENT OF TUMOURS AND TUMOUR METASTASES SIENA BIOTECH S.P.A. (IT) 2015-07-30 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
WO-2012076413-A1 COMPOUND FOR THE TREATMENT OF TUMOURS AND TUMOUR METASTASES SIENA BIOTECH S.P.A. (IT) 2012-06-14 WO disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210669-A1 COMPOUND FOR THE TREATMENT OF TUMOURS AND TUMOUR METASTASES SMO, SHH, GLI1 RAB9A 1051/4885LMNA 4727/4885MEN1 615/4885
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A RAB9A 2507/4885LMNA 2086/4885MEN1 2661/4885
US-20170196845-A1 PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE FABP1, LIPC, SLC10A1 RAB9A 2970/4885LMNA 1257/4885MEN1 4206/4885
US-20170210737-A1 IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING FGFR1, TYRO3, STAT6 RAB9A 3095/4885LMNA 3744/4885MEN1 1937/4885
US-10023567-B2 Imidazole and thiazole compositions for modifying biological signaling FGFR1, TYRO3, STAT6 RAB9A 3095/4885LMNA 3744/4885MEN1 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.